Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Plus Therapeutics (Nasdaq: PSTV) received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
The extension does not affect the company's current listing and gives Plus until May 11, 2026 to achieve a closing bid of at least $1.00 for a minimum of 10 consecutive business days, at which point Nasdaq would confirm compliance in writing. The company cautioned there is no assurance it will regain compliance even if other listing requirements remain met.
Plus Therapeutics (Nasdaq: PSTV) ha ottenuto una estensione di 180 giorni da Nasdaq per recuperare la conformità al requisito del prezzo di base minimo di $1.00 secondo la regola di quotazione di Nasdaq 5550(a)(2).
L'estensione non influisce sull'attuale stato di quotazione dell'azienda e concede a Plus fino al 11 maggio 2026 per raggiungere un prezzo di chiusura di almeno $1.00 per un minimo di 10 giorni lavorativi consecutivi, al termine dei quali Nasdaq confermerebbe per iscritto la conformità. L'azienda avverte che non vi è alcuna garanzia che la conformità sarà ripristinata anche se gli altri requisiti di quotazione restano soddisfatti.
Plus Therapeutics (Nasdaq: PSTV) recibió una extensión de 180 días de Nasdaq para volver a cumplir con el requisito de precio de compra mínimo de $1.00 bajo la Regla de Listado 5550(a)(2).
La extensión no afecta el listado actual de la empresa y otorga a Plus hasta el 11 de mayo de 2026 para lograr un precio de cierre de al menos $1.00 durante un mínimo de 10 días hábiles consecutivos, momento en el cual Nasdaq confirmaría por escrito el cumplimiento. La empresa advirtió que no hay garantía de que se vuelva a cumplir, incluso si se cumplen otros requisitos de listado.
Plus Therapeutics (나스닥: PSTV)은 나스닥으로부터 $1.00 최소 매수가격 요건을 회복하기 위한 180일 연장을 받았습니다. 이는 나스닥 상장 규정 5550(a)(2)에 따른 것입니다.
연장은 회사의 현재 상장에는 영향을 주지 않으며 Plus에 2026년 5월 11일까지 $1.00 이상의 종가를 연속된 10거래일 동안 달성해야 한다고 합니다. 이 시점에서 나스닥은 서면으로 준수 여부를 확인해줄 것입니다. 회사는 다른 상장 요건이 충족되더라도 준수를 회복할 수 있다는 보장이 없다고 주의했습니다.
Plus Therapeutics (Nasdaq : PSTV) a obtenu une extension de 180 jours de Nasdaq pour regagner la conformité avec l’exigence du cours d’ouverture minimum de 1,00 $ selon la règle de cotation Nasdaq 5550(a)(2).
L’extension n’affecte pas la cotation actuelle de l’entreprise et donne à Plus jusqu’au 11 mai 2026 pour réaliser un cours de clôture d’au moins 1,00 $ sur au moins 10 jours ouvrables consécutifs, à quel moment Nasdaq confirmerait la conformité par écrit. L’entreprise avertit qu’il n’y a aucune garantie de regagner la conformité même si les autres exigences de cotation restent satisfaites.
Plus Therapeutics (Nasdaq: PSTV) erhielt eine 180-tägige Verlängerung von der Nasdaq, um die Compliance mit der Minimuhöchstpreis von 1,00 $ gemäß der Nasdaq Listing Rule 5550(a)(2) wiederherzustellen.
Die Verlängerung beeinträchtigt nicht die aktuelle Listung des Unternehmens und gibt Plus bis zum 11. Mai 2026 Zeit, einen Schlusskurs von mindestens 1,00 $ über mindestens 10 aufeinanderfolgende Handelstage zu erreichen, woraufhin Nasdaq die Compliance schriftlich bestätigen würde. Das Unternehmen warnt, dass es keine Garantie gibt, die Compliance wiederzuerlangen, selbst wenn andere Listing-Anforderungen erfüllt bleiben.
Plus Therapeutics (ناسداك: PSTV) تلقّت تمديداً لمدة 180 يوماً من ناسداك لاستعادة الامتثال لمتطلب حد السعر الإغلاق الأدنى 1.00 دولار بموجب قاعدة الإدراج 5550(a)(2) في ناسداك.
الامتداد لا يؤثر على قائمة الشركة الحالية ويمنح Plus حتى 11 مايو 2026 لتحقيق سعر إغلاق لا يقل عن 1.00 دولار لمدة 10 أيام عمل متتالية، عندها ستؤكد ناسداك الامتثال كتابياً. حذرت الشركة من أنه لا يوجد ضمان بأنها ستعيد الامتثال حتى لو تم استيفاء بقية متطلبات الإدراج.
- Nasdaq granted a 180-day extension to regain compliance
- Compliance deadline set for May 11, 2026
- No near-term reverse stock split required to meet rule
- Must achieve $1.00 closing price for 10 consecutive business days
- Company stated no assurance it will regain compliance
No near-term Reverse Stock Split required to meet Bid Price Rule
HOUSTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces it has received an additional 180-day extension period from the Nasdaq Listing Qualifications Department (the “Nasdaq Staff”) to regain compliance with the
The extension notice has no immediate effect on the continued listing status of the Company’s common stock on the Nasdaq Capital Market (“Nasdaq”) under the symbol “PSTV.” The Company has until May 11, 2026, to meet the Minimum Bid Price Requirement. If at any time during the additional 180-calendar-day extension, the closing bid price of the common stock is at least
There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement, even if it maintains compliance with the other listing requirements.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com.
About CNSide Diagnostic, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases.
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including the Company’s ability to maintain compliance with the Minimum Bid Price Requirement and other Nasdaq’s continued listing rules. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “will,” “potential,” “anticipating,” “planning,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the price and volatility of the Company’s common stock; the Company’s liquidity and capital resources and its ability to raise additional cash; market conditions, product performance, litigation or potential litigation; and, competition within the cancer diagnostics and therapeutics field. This list of risks, uncertainties, and other factors is not complete. The Company discusses some of these matters more fully, as well as certain risk factors that could affect the Company’s business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements the Company makes may turn out to be wrong and can be affected by inaccurate assumptions the Company might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
CORE IR
investor@plustherapeutics.com
FAQ
What did Plus Therapeutics (PSTV) announce on November 17, 2025 about Nasdaq compliance?
What is the deadline for PSTV to meet Nasdaq's minimum bid price requirement?
How does PSTV regain compliance with Nasdaq's bid price rule?
Does the Nasdaq extension affect PSTV's current listing status?
Will Plus Therapeutics need a reverse stock split to meet the bid price rule now?
